Forgot Password

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Pharmaceuticals » HPH-1601015
  • Global Ophthalmology Drug & Devices Market insights, Opportunities, Analysis, Market Shares and Forecast 2017 – 2023

  • Publish: January 2016 | Report Code: HPH-1601015

* For discount/customization and buying a particular chapter click here or write to us at sales@occamsresearch.com

Global ophthalmic drug & devices market is estimated to rise with approx. 7% CAGR during forecast period 2016 – 2023. The global ophthalmic drugs and devices market  owing to rising geriatric population and the rising prevalence of eye related disorders such as glaucoma and cataract are acting as a driver for the ophthalmic drug market and mounting its demand. Global ophthalmic drug & devices market is primarily driven by following factors:

  • Rise in healthcare expenditure
  • Increasing elderly population
  • Technological advancement
  • Innovation leading to development of new ophthalmology drugs
  • Rising prevalence rate of eye diseases





The global ophthalmic drugs & device market is poised to display a healthy growth over the forecast period attributed to various influencing factors that are set to drive the market towards an exceptional growth path. Some of the factors are the mounting prevalence of eye diseases and eye related disorders such as glaucoma and cataract, along with the expanding pool of geriatric population across the globe. this, in addition to the various pending regulatory approvals to new ophthalmic drugs that are about to be given a green signal during the forecast period and the growing awareness among people, especially in the emerging economies are creating significant opportunities for the market. Moreover, rapid technological advancements resulting in combining drugs and device therapy that are being used to treat an extensive range of eye related disorder coupled with various innovation has given way to various implants such as ODTx, MicroPump, transscleral and Encapsulated cell therapy are expected to provide further boost to the ophthalmic drugs market. All these factors are further intensified with increasing healthcare expenditure by various economies across the globe which is expected to propel the growth of the market. However, factors such as expiration of patents, drying pipelines and major slowdowns in economies may hamper the market growth.

Source: OBRC Analysis

The global ophthalmic drug & devices market segments include  device, vision care, drug, type of disease, therapeutics and end-user.  Device segment is sub segmented into:

  • OPHTHALMIC DIAGNOSTIC & MONITORING EQUIPMENT
  • OPHTHALMOLOGY SURGERY DEVIC



 Vision care is sub-segmented into:

  • CONTACT LENS   SPECTACLES
  • EYE EXAMS



Drug segment is sub-segmented into:

  • PRESCRIPTION TYPE
  • DRUG DELIVERY TYPES



Type of disease segment is sub-segmented into:

  • GLAUCOMA DRUG
  • RETINAL DISORDER  
  • DRY EYE DRUG  
  • ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS






Therapeutics segment is sub-segmented into:

  • DIABETIC MACULAR EDEMA
  • EYE CANCER  
  • DIABETIC RETINOPATHY
  • RETINAL VEIN OCCLUSION  
  • AGE-RELATED MACULAR DEGENERATION 
  • CONJUNCTIVITIS
  • DRY EYE  
  • GLAUCOMA
  • KERATITIS












End-user segment is sub-segmented into:

  • HOSPITALS
  • EYE CLINICS  
  • DIAGNOSTIC CENTERS
  • PATIENTS






The revenue for the above end-user segments are specific to the ophthalmic drug and device market. however, the total revenue of end-users in general has been excluded from the scope of the report. Also, the total market revenue has been calculated by summing up type and therapeutics segment.

Geographically, the global ophthalmic drug & devices market has been segmented on the basis of four major region, which include:

  • North America (U.S. & Canada)
  • Asia Pacific (China, India, Japan, RoAPAC)
  • Europe (UK, France, Germany, RoE)
  • Rest of World






North America being the largest market  share of the total market share, followed by Europe and Asia Pacific. The North American market is driven by high awareness, greater availability of drugs due to presence of major players, and an elaborate regulatory framework. North America (US) due to increased initiatives to reduce blindness, as well as other related disorders amongst the geriatric population,   Asia Pacific is expected to be one of the fastest growing markets for ophthalmic drugs in the world during the forecasted period, as the elderly population is more prone to suffer from eye related disorders due to age.

The demand for multispecialty hospitals has been rising significantly. Furthermore, governments in various countries are spending heavily to develop multispecialty hospitals and to improve the existing healthcare infrastructure. The rising public and private investment in hospitals is expected to create significant opportunities for the market. By end users, the market is segmented into various subtypes, viz. hospitals, eye clinics, diagnostic centers, and patients’ ophthalmic drugs. However, eye clinic segment is expected to have the fastest growth due to the rapid development of lightweight and compact respiratory care devices that are easier to operate. On the basis of revenue, hospital care market has the highest market share, and homecare market is expected to have the fastest growth rate.

The major market players of the global ophthalmic drug and devices market are:

  • ABBOT LABORATORIES
  • AKORN
  • ALLERGAN INC.
  • BAYER
  • OTHERS





Detailed analysis of these companies provided in this report comprises: Overview, SCOT Analysis, Product Portfolio, Strategic Initiative and Strategic Analysis.

These companies using various strategies such as merger & acquisition, collaboration, partnership and product launching. Example,   Bayer and DelSiTech partner to develop innovative drug delivery technology for ophthalmology in September 29, 2016. This partnership will support in innovative treatment options for a range of different eye diseases.

Allergan acquired ForSight VISION5 in 2016 for expanding its eye-care offerings.

Why to buy the report:

This report will provide you:

  • Provide you the business strategies adopted by market player such as Bayer and DelSiTech partner to develop innovative drug delivery technology for ophthalmology in September 29, 2016.  
  • Provide in detail the different segments such as by therapeutics, type and end-user of global ophthalmic drug & devices market.
  • Provide you the patent analysis of the ophthalmic drug & devices market.
  • Identify and understand the strength, opportunities, challenges and threat of the ophthalmic drug & devices market.
  • Provide revenues of major players of the market such as ABOTT, Bayers and so on.  .
  • Provide you various the regulatory policies which are affecting the global ophthalmic drug & devices market.








How we are different from others:

At Occams we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global ophthalmic drug & devices market offers the longest chain of market segmentation covering major market segmentation based on therapeutics, type and end-user. The report tracks the major market trends in the global ophthalmic drug & devices market such as high prevalence rate  of eye diseases  and increase in minimal invasive surgeries and   so on.  For each market segments covered in global ophthalmic drug & devices market report, we provide opportunity matrix, and DROC analysis, that enable the clear growth assessment across each market segment. The report discusses competitive landscape of the ophthalmic drug & devices market industry, with giving extensive strategy analysis of more than 15 companies. Moreover, the report discusses various models such as 360-degree analysis, See Saw analysis, and Porter five force model and so on. For the high-level analysis in the report we provide a comparative analysis of historic and current year data. 

Key findings of the global ophthalmic drug & devices market.

  •  Increase in  the eye disorder and increased FDA approvals are fueling growth in global ophthalmic drug & devices market.
  • North America is anticipated to account the largest revenue share in 2016.
  • Glaucoma has the largest market share in ophthalmic treatment segment.
  • Increasing government support.
  • Partnership  is the key strategy adopted by the various market players of global  ophthalmic drug & device market.
  • Eye clinic segment of end-user segment is expected to have the fastest growth due to the rapid development of lightweight and compact respiratory care devices that are easier to operate.
1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
 
2. MARKET OVERVIEW
2.1. GLOBAL OPHTHALMOLOGY DRUGS & DEVICES MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. TOTAL MARKET ANALYSIS
2.4.1. TOP 5 FINDINGS
2.4.2. TOP 5 OPPORTUNITY MARKETS
2.4.3. TOP 5 COMPANIES
2.4.4. TOP 3 COMPETITIVE STRATEGIES
2.5. ESTIMATION ANALYSIS
2.6. STRATEGIC ANALYSIS
2.6.1. INVESTMENT VS. ADOPTION MODEL
2.6.2. 360-DEGREE INDUSTRY ANALYSIS
2.6.3. PORTERS 5 FORCE MODEL
2.6.4. SEE-SAW ANALYSIS
2.6.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.7. COMPETITIVE ANALYSIS
2.7.1. MARKET SHARE ANALYSIS 
2.8. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.8.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.8.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.8.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
 
3. MARKET DETERMINANTS 
3.1. MARKET DRIVERS
3.1.1. GLOBAL INCREASE IN PREVALENCE RATES OF EYE DISEASES
3.1.2. INCREASING PREVALENCE OF DIABETES INCREASES PROBABILITY OF OPHTHALMIC DISORDERS
3.1.3. RISE IN HEALTHCARE EXPENDITURE ACROSS THE GLOBE
3.1.4. INNOVATIONS LEADING TO DEVELOPMENT OF NEW OPHTHALMOLOGY DRUGS
3.2. MARKET RESTRAINTS
3.2.1. MAJOR DRUGS GOING OFF PATENT
3.2.2. LOW AWARENESS RELATED TO OPHTHALMOLOGY DRUGS AND DEVICES TO HINDER THE MARKET GROWTH
3.3. MARKET OPPORTUNITIES
3.3.1. UNTAPPED EMERGING MARKETS PRESENT SIGNIFICANT GROWTH OPPORTUNITIES
3.3.2. RISING DEMAND FOR INTRAOCULAR LENSES AND PHACOEMULSIFICATION DEVICES 
3.4.   MARKET CHALLENGES 
3.4.1. RISK ASSOCIATED WITH THE OCULAR DISEASES
3.4.2. SLOW ECONOMIC GROWTH IN DEVELOPING REGIONS MAY AFFECT THE OPHTHALMOLOGY DRUG AND DEVICE MARKET
 
4. MARKET SEGMENTATION 
4.1. GLOBAL OPHTHALMOLOGY DRUGS & DEVICES MARKET BY DEVICES
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION 
4.1.5.1. GLOBAL DIAGNOSTIC & MONITORING MARKET 
4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.1.3. KEY PLAYERS & KEY PRODUCTS 
4.1.5.1.4. KEY CONCLUSIONS
4.1.5.1.5. MARKET SUB-SEGMENTS
4.1.5.1.5.1. OPTICAL COHERENCE TOMOGRAPHY (OCT) SCANNERS    
4.1.5.1.5.2. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS    
4.1.5.1.5.3. FUNDUS CAMERA    
4.1.5.1.5.4. OPHTHALMOSCOPES    
4.1.5.1.5.5. RETINOSCOPE    
4.1.5.1.5.6. OTHERS
 
 
4.1.5.2. GLOBAL SURGERY DEVICES MARKET 
4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.2.3. KEY PLAYERS & KEY PRODUCTS 
4.1.5.2.4. KEY CONCLUSIONS
4.1.5.2.5. MARKET SUB-SEGMENTS
4.1.5.2.5.1. CATARACT SURGERY DEVICES
4.1.5.2.5.2. GLAUCOMA SURGERY DEVICES
4.1.5.2.5.3. GLAUCOMA SURGERY DEVICES
4.1.5.2.5.4. VITREORETINAL SURGERY DEVICES
4.1.5.3. GLOBAL VISION CARE MARKET 
4.1.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.3.3. KEY PLAYERS & KEY PRODUCTS 
4.1.5.3.4. KEY CONCLUSION
4.2. GLOBAL OPHTHALMOLOGY DRUGS & DEVICES MARKET BY DRUGS
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION 
4.2.5.1. GLOBAL GLAUCOMA DRUG MARKET 
4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.1.4. KEY CONCLUSIONS
4.2.5.2. GLOBAL DRY EYE DRUG MARKET 
4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.2.4. KEY CONCLUSIONS
4.2.5.3. GLOBAL ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG MARKET 
4.2.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.3.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.3.4. KEY CONCLUSIONS
4.2.5.4. GLOBAL RETINAL DISORDER MARKET 
4.2.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.4.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.4.4. KEY CONCLUSIONS
4.2.5.5. GLOBAL others MARKET 
4.2.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.5.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.5.4. KEY CONCLUSIONS
 
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS AND ACQUISITIONS
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
 
6. GEOGRAPHIC ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL OPHTHALMOLOGY DRUGS & DEVICES MARKET BY REGION 2014-2023 ($ MILLION)
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S. 
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.3.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.4.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.5.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.5.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA 
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
 
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. STRATEGIC INITIATIVES 
7.1.4. SCOT ANALYSIS
7.1.5. STRATEGIC ANALYSIS
7.2. ALLERGAN, INC.
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. STRATEGIC INITIATIVES 
7.2.4. SCOT ANALYSIS
7.2.5. STRATEGIC ANALYSIS
7.3. BAYER AG
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. STRATEGIC INITIATIVES 
7.3.4. SCOT ANALYSIS 
7.3.5. STRATEGIC ANALYSIS
 
7.4. CARL ZEISS MEDITEC AG
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. STRATEGIC INITIATIVES 
7.4.4. SCOT ANALYSIS 
7.4.5. STRATEGIC ANALYSIS
7.5. GLAXOSMITHKLINE
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. STRATEGIC INITIATIVES 
7.5.4. SCOT ANALYSIS 
7.5.5. STRATEGIC ANALYSIS
 
7.6. JOHNSON & JOHNSON
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. STRATEGIC INITIATIVES 
7.6.4. SCOT ANALYSIS
7.6.5. STRATEGIC ANALYSIS
7.7. MERCK & CO., INC.
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. STRATEGIC INITIATIVES 
7.7.4. SCOT ANALYSIS
7.7.5. STRATEGIC ANALYSIS
7.8. NOVARTIS AG
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. STRATEGIC INITIATIVES 
7.8.4. SCOT ANALYSIS 
7.8.5. STRATEGIC ANALYSIS
7.9. PFIZER, INC.
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. STRATEGIC INITIATIVES 
7.9.4. SCOT ANALYSIS 
7.9.5. STRATEGIC ANALYSIS
7.10. ROCHE HOLDING AG
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. STRATEGIC INITIATIVES 
7.10.4. SCOT ANALYSIS 
7.10.5. STRATEGIC ANALYSIS
7.11. ZIEMER GROUP HOLDING AG
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. STRATEGIC INITIATIVES 
7.11.4. SCOT ANALYSIS 
7.11.5. STRATEGIC ANALYSIS
7.12. SUN PHARMACEUTICALS INDUSTRIES, LTD.
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. STRATEGIC INITIATIVES 
7.12.4. SCOT ANALYSIS 
7.12.5. STRATEGIC ANALYSIS
7.13. BAUSCH & LOMB
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. STRATEGIC INITIATIVES 
7.13.4. SCOT ANALYSIS
7.13.5. STRATEGIC ANALYSIS
7.14. TOPCON
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. STRATEGIC INITIATIVES 
7.14.4. SCOT ANALYSIS
7.14.5. STRATEGIC ANALYSIS
7.15. SANTEN PHARMACEUTICAL CO., LTD.
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. STRATEGIC INITIATIVES 
7.15.4. SCOT ANALYSIS
7.15.5. STRATEGIC ANALYSIS
 
LIST OF TABLES
 
1. GLOBAL OPHTHALMOLOGY DRUGS & DEVICES MARKET BY DEVICES 2014-2023 ($ MILLION)
2. GLOBAL DIAGNOSTIC & MONITORING MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
3. GLOBAL OPHTHALMOLOGY DRUGS & DEVICES MARKET BY DIAGNOSTIC & MONITORING
4. GLOBAL SURGERY DEVICES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
5. GLOBAL OPHTHALMOLOGY DRUGS & DEVICES MARKET BY SURGERY DEVICES
6. GLOBAL VISION CARE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
7. GLOBAL OPHTHALMOLOGY DRUGS & DEVICES MARKET BY DRUGS 2014-2023 ($ MILLION)
8. GLOBAL GLAUCOMA DRUG MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
9. GLOBAL DRY EYE DRUG MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
10. GLOBAL ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
11. GLOBAL RETINAL DISORDER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
12. GLOBAL OTHERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
13. NORTH AMERICA OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
14. EUROPE OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
15. ASIA PACIFIC OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
16. REST OF THE WORLD OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
 
LIST OF FIGURES
 
1. GLOBAL DIAGNOSTIC & MONITORING MARKET
2. GLOBAL OPTICAL COHERENCE TOMOGRAPHY (OCT) SCANNERS MARKET
3. GLOBAL OPHTHALMIC ULTRASOUND IMAGING SYSTEMS MARKET
4. GLOBAL FUNDUS CAMERA MARKET
5. GLOBAL OPHTHALMOSCOPES    MARKET
6. GLOBAL RETINOSCOPE MARKET
7. GLOBAL OTHERS MARKET 
8. GLOBAL CATARACT SURGERY DEVICES MARKET 
9. GLOBAL GLAUCOMA SURGERY DEVICES MARKET
10. GLOBAL GLAUCOMA SURGERY DEVICES MARKET
11. GLOBAL VITREORETINAL SURGERY DEVICES MARKET 
12. GLOBAL VISION CARE MARKET
13. GLOBAL GLAUCOMA DRUG MARKET 
14. GLOBAL DRY EYE DRUG MARKET
15. GLOBAL ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG MARKET
16. GLOBAL RETINAL DISORDER MARKET
17. GLOBAL OTHERS MARKET 
18. UNITED STATES (U.S.) OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
19. CANADA OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
20. UNITED KINGDOM (UK) OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
21. FRANCE OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
22. GERMANY OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
23. SPAIN OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
24. ROE OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
25. INDIA OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
26. CHINA OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
27. JAPAN OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
28. AUSTRALIA OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
29. ROAPAC OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
30. LATIN AMERICA OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
31. MENA OPHTHALMOLOGY DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)
 

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample


UPCOMING REPORTS

No upcoming reports available under this subcategory.
credit card

CONNECT WITH US

Occams Business Research & Consulting Pvt. Ltd.

Landline: 0731 4042636 

Handheld: +91 9713031393

Email: sales@occamsresearch.com

 

 

Go To Top
viewthroughconversion